SCHEMBL20364348

SCHEMBL20364348

Cc1cccc(Cn2cnc(NC(=O)c3cnc4c(c3)CCN(C(=O)OC(C)(C)C)C4)c2)c1

nearest known ligand 0.41

Predicted protein targets (top 12)

geneUniProtsupporting neighboursconfidence
MAP3K5 Q99683 9/20 0.41
TAS2R8 Q9NYW2 1/20 0.40
KDM1A O60341 1/20 0.40
RIPK1 Q13546 1/20 0.38
MKNK1 Q9BUB5 1/20 0.37
THRB P10828 1/20 0.36
ESR2 Q92731 1/20 0.36
GCK P35557 1/20 0.36
CDK5 Q00535 1/20 0.36
CDK5R1 Q15078 1/20 0.36
GSK3B P49841 1/20 0.36
GAA P10253 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20364356 0.92 MAP3K5 (0.41) MAP3K5TAS2R8RIPK1MKNK1ESR2
SCHEMBL20367218 0.90 KDM4C (0.42) MAP3K5
SCHEMBL20364347 0.90 TAS2R8 (0.49) MAP3K5TAS2R8KDM1AMKNK1THRB
SCHEMBL20364350 0.90 TAS2R8 (0.49) MAP3K5TAS2R8KDM1AESR2
SCHEMBL20364335 0.86 MAP3K5 (0.38) MAP3K5TAS2R8RIPK1ESR2GCK
SCHEMBL20364368 0.85 MAP3K5 (0.40) MAP3K5TAS2R8ESR2GCK
SCHEMBL20364352 0.85 MAP3K5 (0.52) MAP3K5
SCHEMBL20364355 0.85 TAS2R8 (0.47) MAP3K5TAS2R8KDM1ARIPK1CDK5
SCHEMBL20364334 0.83 MAP3K5 (0.43) MAP3K5TAS2R8KDM1ARIPK1MKNK1
SCHEMBL20364349 0.83 MKNK1 (0.42) MAP3K5KDM1AMKNK1GCKCDK5

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20180194773-A1 BICYCLIC HETEROCYCLIC AMIDE DERIVATIVE SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) 2018-07-12 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180194773-A1 BICYCLIC HETEROCYCLIC AMIDE DERIVATIVE NR0B1, NR2E1, NR0B2 MAP3K5 3026/4885TAS2R8 2479/4885KDM1A 655/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.